SCHEMBL5282646

SCHEMBL5282646

Cc1cccc2oc(=O)n(CC(=O)Oc3c(F)c(F)c(F)c(F)c3F)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
PKM P14618 1/20 0.38
CYP2C19 P33261 1/20 0.38
IDO1 P14902 1/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
POLB P06746 1/20 0.37
RECQL P46063 1/20 0.37
HPGD P15428 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
CDYL2 Q8N8U2 1/20 0.36
CDYL Q9Y232 1/20 0.36
CDY1; CDY1B Q9Y6F8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5286548 0.81 HPGD (0.58) KMT2AMEN1TSHRCYP1A2CYP2D6
SCHEMBL15157087 0.80 KMT2A (0.45) KMT2AMEN1TDP1L3MBTL1TSHR
SCHEMBL5293998 0.79 KMT2A (0.47) KMT2ACYP1A2CYP2D6PKMCYP2C19
SCHEMBL5558972 0.78 HPGD (0.60) KMT2AMEN1CYP1A2CYP2D6PKM
SCHEMBL5282527 0.77 KMT2A (0.44) KMT2AMEN1TDP1L3MBTL1TSHR
SCHEMBL5290934 0.76 MIF (0.50) KMT2AMEN1L3MBTL1CYP1A2CYP2D6
SCHEMBL5289506 0.76 L3MBTL1 (0.61) KMT2AMEN1L3MBTL1TSHRPOLB
SCHEMBL20082376 0.74 SMN1; SMN2 (0.46) KMT2ACYP2C19IDO1POLBRECQL
SCHEMBL20355705 0.72 ALDH1A1 (0.42) CYP1A2CYP2C19IDO1RECQLHPGD
SCHEMBL16186530 0.71 ALDH1A1 (0.39) KMT2AMEN1L3MBTL1TSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 KMT2A 4422/4885MEN1 2853/4885TDP1 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.